The obesity drug market is entering a new competitive phase.

The first question was whether GLP-1 therapies could transform obesity treatment. They already have.

Sample Report: https://lnkd.in/den8-Uv2

The next question is much bigger:

What will define the next generation of obesity medicines — and which companies will lead it?

The market is rapidly moving beyond first-generation GLP-1 therapies such as semaglutide and toward oral treatments, dual and triple agonists, combination therapies, improved tolerability, longer-term weight management, and broader metabolic indications.

This emerging phase could reshape not only obesity treatment, but also the competitive strategies of pharmaceutical companies, biotech firms, investors, healthcare providers and payers.

From Weekly Injections to GLP-1 2.0

For years, injectable GLP-1 therapies dominated the conversation.

Products such as Ozempic, Wegovy and Mounjaro helped establish a new standard for pharmacological weight management. But the next phase of competition is already taking shape.

The focus is shifting toward five major areas:

• More convenient oral therapies
• Greater weight-loss efficacy
• Dual and triple hormone agonists
• Long-term weight maintenance
• Expansion into broader metabolic diseases

Novo Nordisk: Taking GLP-1 Beyond Injections

Novo Nordisk is pushing the category toward oral obesity treatment with oral Wegovy.

The company reported more than 3 million U.S. prescriptions for oral Wegovy by June 2026, highlighting the potential demand for a pill-based alternative to injectable therapy.

The strategic opportunity is significant.

If oral GLP-1 therapies can deliver competitive efficacy while improving convenience and patient acceptance, they could expand the addressable obesity-treatment population and create another major commercial segment.

Eli Lilly: Retatrutide and the Triple-Agonist Race

Eli Lilly is taking the next step with investigational retatrutide.

The molecule targets GIP, GLP-1 and glucagon receptors, making it a triple agonist rather than a conventional GLP-1 or dual GIP/GLP-1 therapy.

In the TRIUMPH-1 study, retatrutide delivered up to 28.3% average weight loss at 80 weeks with the 12 mg dose, according to the reported trial results.

If these results translate into successful Phase 3 development and regulatory approvals, retatrutide could establish a new efficacy benchmark for obesity medicines.

Viking Therapeutics: Oral and Injectable Competition

Viking Therapeutics is also building a position in the next generation of metabolic therapies with VK2735, a GLP-1/GIP dual agonist.

The company is developing both injectable and oral formulations, creating a strategy that could address different patient and prescribing preferences.

The oral formulation is particularly important because convenience could become a major differentiator as more obesity medicines enter the market.

The Competition Is Getting Crowded

The next wave of obesity and metabolic-drug development extends far beyond Novo Nordisk and Eli Lilly.

Companies including Amgen, Roche, Pfizer, Structure Therapeutics, Zealand Pharma and Regeneron are pursuing different approaches to improve efficacy, tolerability, convenience and treatment duration.

This creates a much more complex competitive landscape.

The future market may not be dominated by a single mechanism or company. Instead, different therapies could occupy different positions based on patient profile, indication, price, administration method, efficacy and payer coverage.

The Role of Clinical Research

The development of next-generation obesity therapies is also being shaped by leading researchers and clinical investigators.

Ania Jastreboff, MD, PhD, a leading obesity-medicine researcher and investigator in Lilly’s retatrutide development program, has been closely involved in research examining how next-generation metabolic therapies could change obesity treatment.

As the science advances, clinical evidence will increasingly determine which mechanisms can move from promising pipeline assets to commercially successful medicines.

What Does “GLP-1 2.0” Actually Mean?

GLP-1 2.0 is more than simply the next obesity drug.

It represents a broader shift in how pharmaceutical companies approach weight loss, metabolic health and chronic disease management.

Here are the major competitive battlegrounds.

1. Oral vs. Injectable

Can oral therapies deliver efficacy that is competitive with injections while offering greater convenience?

A successful oral obesity medicine could reduce some of the barriers associated with injectable administration and potentially improve patient acceptance.

But convenience alone will not be enough.

The key question will be:

Can oral therapies deliver the right balance of efficacy, tolerability, dosing convenience and adherence?

2. Single vs. Multi-Agonists

The industry is moving from single-pathway therapies toward dual and triple agonists.

The potential advantage is broader biological activity and potentially greater weight reduction.

The competitive question is whether increasingly complex mechanisms can deliver meaningful clinical advantages without creating unacceptable tolerability or safety challenges.

3. Weight Loss vs. Long-Term Weight Maintenance

Achieving weight loss is only one part of the challenge.

Long-term maintenance remains critical because obesity is a chronic disease and many patients may require continued treatment.

The next generation of therapies will therefore be judged not only by:

“How much weight can patients lose?”

but also:

“How effectively can that weight loss be maintained?”

This could create opportunities for maintenance therapies, combination strategies and longer-duration treatment approaches.

4. Obesity vs. Broader Metabolic Health

The commercial opportunity extends well beyond obesity.

GLP-1 and next-generation metabolic therapies are being evaluated across areas including:

• Cardiovascular disease
• Type 2 diabetes
• MASH/MASLD
• Obstructive sleep apnea
• Chronic kidney disease
• Osteoarthritis
• Other metabolic complications

This expansion could significantly increase the total addressable market for successful therapies.

5. Efficacy vs. Access

The most effective drug may not automatically become the biggest commercial winner.

As competition increases, pharmaceutical companies will have to balance:

• Clinical efficacy
• Safety and tolerability
• Pricing
• Insurance coverage
• Reimbursement
• Dosing frequency
• Drug supply
• Patient adherence
• Real-world outcomes

The winning product may ultimately be the therapy that delivers the best overall value, rather than simply the highest percentage of weight loss.

The Real Competitive Question

The obesity-drug market is moving toward a much more sophisticated competitive environment.

Knowing that a company has a GLP-1, GIP/GLP-1 or triple-agonist program in development is no longer enough.

The important strategic questions are:

Which molecule can win?

In which indication?

Against which competitor?

At what price?

With what reimbursement strategy?

And in which geographic markets?

These questions will become increasingly important for pharmaceutical companies, biotech firms, investors, CDMOs and healthcare strategists.

How We Analyze the GLP-1 Market

At Towards Healthcare Research & Consulting, we look beyond individual drugs and pipeline announcements.

Our market intelligence can help stakeholders evaluate the commercial and competitive landscape through:

• TAM / SAM / SOM analysis
• Competitor and pipeline benchmarking
• Clinical trial tracking
• Company and drug benchmarking
• Pricing and reimbursement intelligence
• Regulatory landscape analysis
• M&A and licensing intelligence
• Market-entry strategy
• Patient and physician insights

The objective is not simply to identify who has a GLP-1 in development.

It is to understand where the opportunity is, who is best positioned to capture it, and what could determine commercial success.

The Next Era of Obesity Treatment

The first era of GLP-1 therapy proved that pharmacological treatment could fundamentally change the obesity market.

GLP-1 2.0 could determine who controls the next phase.

Oral therapies, dual agonists, triple agonists and broader metabolic indications are creating a much larger competitive battlefield.

The winners will likely be companies that can combine clinical differentiation with affordability, scalability, access, adherence and strong real-world outcomes.

The obesity market is no longer simply about Ozempic vs. Mounjaro.

The next battle is about what comes after them.

Explore the GLP-1 Market

Our GLP-1 sample report brings together key drugs, companies, pipelines and market insights in one view.